MicroRNA-375 suppresses extracellular matrix degradation and invadopodial activity in head and neck squamous cell carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 11, 2015, Pages 1349-1361

  Jimenez, Lizandra ^a   Sharma, Ved P ^a   Condeelis, John ^a   Harris, Thomas ^a   Ow, Thomas J ^a   Prystowsky, Michael B ^a   Childs, Geoffrey ^a   Segall, Jeffrey E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; GELATINASE B; KALLIKREIN; KLK10 PROTEIN, HUMAN; KLK6 PROTEIN, HUMAN; MICRORNA; MIRN375 MICRORNA, HUMAN; MMP9 PROTEIN, HUMAN; PROTEIN BINDING; PROTEINASE; PROTEOME; SERINE PROTEINASE;

CELL SURFACE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURFACE EXTENSIONS; CORTACTIN; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; KALLIKREINS; MATRIX METALLOPROTEINASE 9; MICRORNAS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEOME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES;

EID: 84945981377     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0471-OA     Document Type: Article

References (100)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63 (1): 11-30.
2. Url C, Schartinger VH, Riechelmann H, et al. Radiological detection of extracapsular spread in head and neck squamous cell carcinoma (HNSCC) cervical metastases. Eur J Radiol. 2013; 82 (10): 1783-1787.
3. Oksuz DC, Prestwich RJ, Carey B, et al. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo) -radiotherapy. Radiat Oncol. 2011; 6: 54.
4. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: A retrospective study. Clin Cancer Res. 2004; 10 (11): 3607-3613.
5. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res. 2003; 63 (8): 1727-1730.
6. Haddad RI, Shin DM. Recent advances in head and neck cancer. New Engl J Med. 2008; 359 (11): 1143-1154.
7. Ambros V. microRNAs: Tiny regulators with great potential. Cell. 2001; 107 (7): 823-826.
8. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009; 4: 199-227.
9. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nature Rev Genet. 2008; 9 (2): 102-114.
10. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 2009; 174 (3): 736-745.
11. Harris T, Jimenez L, Kawachi N, et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol. 2012; 180 (3): 917-928.
12. Tu HF, Lin SC, Chang KW. MicroRNA aberrances in head and neck cancer: Pathogenetic and clinical significance. Curr Opin Otolaryngol Head Neck Surg. 2013; 21 (2): 104-111.
13. Singh R, Mo YY. Role of microRNAs in breast cancer. Cancer Biol Ther. 2013; 14 (3): 201-212.
14. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013; 774: 1-20.
15. Wang F, Li Y, Zhou J, et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol. 2011; 179 (5): 2580-2588.
16. Siow MY, Ng LP, Chong VK, et al. Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis. 2014; 20 (4): 345-351.
17. Chang C, Shi H, Wang C, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett. 2012; 531 (2): 204-208.
18. Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther. 2012; 12 (suppl 1): S53-S59.
19. Ding L, Xu Y, Zhang W, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010; 20 (7): 784-793.
20. Jung HM, Patel RS, Phillips BL, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell. 2013; 24 (11): 1638-1648, S1631-S1637.
21. Hui AB, Bruce JP, Alajez NM, et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res. 2011; 17 (24): 7539-7550.
22. Kinoshita T, Nohata N, Yoshino H, et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol. 2012; 40 (1): 185-193.
23. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010; 394 (3): 623-627.
24. Hanahan D,Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144 (5): 646-674.
25. Weaver AM. Invadopodia: Specialized cell structures for cancer invasion. Clin Exp Metastasis. 2006; 23 (2): 97-105.
26. Linder S, Wiesner C, Himmel M. Degrading devices: Invadosomes in proteolytic cell invasion. Annu Rev Cell Dev Biol. 2011; 27: 185-211.
27. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012; 24 (2): 277-283.
28. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: Characteristics, formation and function. Nature Rev Mol Cell Biol. 2011; 12 (7): 413-426.
29. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function. Cancer Res. 2006; 66 (6): 3034-3043.
30. Sharma VP, Eddy R, Entenberg D, Kai M, Gertler FB, Condeelis J. Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Curr Biol. 2013; 23 (21): 2079-2089.
31. Oser M, Yamaguchi H, Mader CC, et al. Cortactin regulates cofilin and NWASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol. 2009; 186 (4): 571-587.
32. Seals DF, Azucena EF Jr, Pass I, et al. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell. 2005; 7 (2): 155-165.
33. Li A, Dawson JC, Forero-Vargas M, et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol. 2010; 20 (4): 339-345.
34. Hayes KE,Walk EL, Ammer AG, Kelley LC, Martin KH,Weed SA. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene. 2013; 32 (40): 4766-4777.
35. Fekete A, G Bogel, Pesti S, Peterfi Z, Geiszt M, Buday L. EGF regulates tyrosine phosphorylation and membrane-Translocation of the scaffold protein Tks5. J Mol Signal. 2013; 8 (1): 8.
36. Burger KL, Learman BS, Boucherle AK, et al. Src-dependent Tks5 phosphorylation regulates invadopodia-Associated invasion in prostate cancer cells. Prostate. 2014; 74 (2): 134-148.
37. Stylli SS, Stacey TT, Verhagen AM, et al. Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. J Cell Sci. 2009; 122 (pt 15): 2727-2740.
38. Abram CL, Seals DF, Pass I, et al. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-Transformed cells. J Biol Chem. 2003; 278 (19): 16844-16851.
39. Oser M, Dovas A, Cox D, Condeelis J. Nck1 and Grb2 localization patterns can distinguish invadopodia from podosomes. Eur J Cell Biol. 2011; 90 (2-3): 181-188.
40. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007; 67 (9): 4227-4235.
41. Ammer AG, Kelley LC, Hayes KE, et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther. 2009; 1 (2): 52-61.
42. Hwang YS, Park KK, Chung WY. Invadopodia formation in oral squamous cell carcinoma: The role of epidermal growth factor receptor signalling. Arch Oral Biol. 2012; 57 (4): 335-343.
43. Hwang YS, Park KK, Cha IH, Kim J, Chung WY. Role of insulin-like growth factor-II mRNA-binding protein-3 in invadopodia formation and the growth of oral squamous cell carcinoma in athymic nude mice. Head Neck. 2012; 34 (9): 1329-1339.
44. Hwang YS, Park KK, Chung WY. Epigallocatechin-3 gallate inhibits cancer invasion by repressing functional invadopodia formation in oral squamous cell carcinoma. Eur J Pharmacol. 2013; 715 (1-3): 286-295.
45. Sharma VP, Entenberg D, Condeelis J. High-resolution live-cell imaging and time-lapse microscopy of invadopodium dynamics and tracking analysis. Methods Mol Biol. 2013; 1046: 343-357.
46. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-image analysis. Nature Methods. 2012; 9 (7): 676-682.
47. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012; 9 (7): 671-675.
48. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120 (1): 15-20.
49. Hoshino D, Jourquin J, Emmons SW, et al. Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCalpha invasive signaling axis. Sci Signal. 2012; 5 (241): Ra66.
50. Parekh A, Weaver AM. Regulation of cancer invasiveness by the physical extracellular matrix environment. Cell Adh Migr. 2009; 3 (3): 288-292.
51. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011; 44 (5): 839-847.
52. Vlachos IS, Kostoulas N, Vergoulis T, et al. DIANA miRPath v.2.0: Investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012; 40 (Web server issue): W498-W504.
53. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: Targets and expression. Nucleic Acids Research. 2008; 36 (Database issue): D149-D153.
54. Oser M, Mader CC, Gil-Henn H, et al. Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia. J Cell Sci. 2010; 123 (pt 21): 3662-3673.
55. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: A focus on MT1-MMP trafficking to invadopodia. J Cell Sci. 2009; 122 (pt 17): 3015-3024.
56. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer. 2012; 51 (5): 473-479.
57. Wang Z, Hong Z, Gao F, Feng W. Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. Mol Cell Biochem. 2013; 383 (1-2): 59-65.
58. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clin Cancer Res. 2009; 15 (19): 6192-6200.
59. de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor {alpha} in breast cancer cells. Cancer Res. 2010; 70 (22): 9175-9184.
60. Hui AB, Lenarduzzi M, Krushel T, et al. Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res. 2010; 16 (4): 1129-1139.
61. Nohata N, Hanazawa T, Kikkawa N, et al. Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genetics. 2011; 56 (8): 595-601.
62. Shen ZY, Zhang ZZ, Liu H, Zhao EH, Cao H. miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression. Exp Ther Med. 2014; 7 (6): 1757-1761.
63. Miao L, Liu K, Xie M, Xing Y, Xi T. miR-375 inhibits Helicobacter pyloriinduced gastric carcinogenesis by blocking JAK2-STAT3 signaling. Cancer Immunol Immunother. 2014; 63 (7): 699-711.
64. Wang Y, Tang Q, Li M, Jiang S, Wang X. MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun. 2014; 444 (2): 199-204.
65. He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012; 31 (28): 3357-3369.
66. Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011; 585 (15): 2467-2476.
67. Xu Y, Jin J, Liu Y, et al. Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2. PloS One. 2014; 9 (7): E99516.
68. Hong S, Noh H, Teng Y, et al. SHOX2 is a direct miR-375 target and a novel epithelial-To-mesenchymal transition inducer in breast cancer cells. Neoplasia. 2014; 16 (4): 279-290, e271-e275.
69. Luo D, Wilson JM, Harvel N, et al. A systematic evaluation of miRNA: MRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med. 2013; 11: 57.
70. Beaty BT, Condeelis J. Digging a little deeper: The stages of invadopodium formation and maturation. Eur J Cell Biol. 2014; 93 (10-12): 438-444.
71. Beaty BT, Sharma VP, Bravo-Cordero JJ, et al. Beta1 integrin regulates Arg to promote invadopodial maturation and matrix degradation. Mol Biol Cell. 2013; 24 (11): 1661-1675, S1-S11.
72. Mader CC, Oser M, Magalhaes MA, et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 2011; 71 (5): 1730-1741.
73. Takkunen M, Hukkanen M, Liljestrom M, Grenman R, Virtanen I. Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia. J Cell Mol Med. 2010; 14 (6B): 1569-1593.
74. Mueller SC, Ghersi G, Akiyama SK, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem. 1999; 274 (35): 24947-24952.
75. Lin CW, Sun MS, Wu HC. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma. Int J Oncol. 2014; 45 (2): 710-718.
76. Lin CW, Sun MS, Liao MY, et al. Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells. Carcinogenesis. 2014; 35 (11): 2425-2435.
77. Martin-Villar E, Borda-d'Agua B, Carrasco-Ramirez P, et al. Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability [published online ahead of print December 8, 2014]. Oncogene. doi: 10.1038/onc.2014.388.
78. Buschman MD, Bromann PA, Cejudo-Martin P,Wen F, Pass I, Courtneidge SA. The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation. Mol Biol Cell. 2009; 20 (5): 1302-1311.
79. Leong HS, Robertson AE, Stoletov K, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014; 8 (5): 1558-1570.
80. Freitas VM, do Amaral JB, Silva TA, et al. Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion. Mol Cancer. 2013; 12: 2.
81. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009; 23 (16): 1882-1894.
82. Le Bras GF, Taylor C, Koumangoye RB, Revetta F, Loomans HA, Andl CD. TGFbeta loss activates ADAMTS-1-mediated EGF-dependent invasion in a model of esophageal cell invasion. Exp Cell Res. 2015; 330 (1): 29-42.
83. Hasegawa H, Senga T, Ito S, Iwamoto T, Hamaguchi M. A role for AP-1 in matrix metalloproteinase production and invadopodia formation of v-Crktransformed cells. Exp Cell Res. 2009; 315 (8): 1384-1392.
84. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993; 8 (2): 395-405.
85. Liu L, Wu J, Ying Z, et al. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res. 2010; 70 (9): 3750-3759.
86. Monsky WL, Lin CY, Aoyama A, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 1994; 54 (21): 5702-5710.
87. O'Brien P, O'Connor BF. Seprase: An overview of an important matrix serine protease. Biochim Biophys Acta. 2008; 1784 (9): 1130-1145.
88. Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002; 277 (32): 29231-29241.
89. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nature Rev Cancer. 2004; 4 (11): 876-890.
90. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: The cancer biomarker family. Cancer Lett. 2007; 249 (1): 61-79.
91. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumor Biol. 2004; 25 (4): 193-199.
92. Magklara A, Mellati AA, Wasney GA, et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003; 307 (4): 948-955.
93. Kapadia C, Ghosh MC, Grass L, Diamandis EP. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun. 2004; 323 (3): 1084-1090.
94. Michael IP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5) , a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005; 280 (15): 14628-14635.
95. Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the Cterminal hemopexin domains. Biochim Biophys Acta. 2011; 1813 (8): 1525-1531.
96. Huang W, Zhong J, Wu LY, et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett. 2007; 251 (1): 78-85.
97. Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2010; 101 (4): 934-940.
98. Pampalakis G, Diamandis EP, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem. 2006; 387 (6): 795-799.
99. Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem. 2006; 387 (6): 773-782.
100. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: Physiologic roles and applications in cancer. Mol Cancer Res. 2004; 2 (5): 257-280.